Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
SPEKTRAX logo — SPEKTRAX is creating an ultra-rapid COVID-19 test kit with a...

SPEKTRAX

SPEKTRAX is creating an ultra-rapid COVID-19 test kit with a handheld device that takes minutes to produce results.

Founded 2020 The Netherlands The Netherlands 11-50 employees Biotechnology

General Information

Company Name SPEKTRAX
Founded Year 2020
Location The Netherlands The Netherlands
Employees 11-50
Industries Biotechnology
Social

Get notified when SPEKTRAX moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About SPEKTRAX

SPEKTRAX is a biotechnology startup based in The Netherlands, founded in 2020. The company is developing an ultra-rapid COVID-19 test kit with a handheld device that promises to generate results within minutes. Utilizing nanotechnology, SPEKTRAX aims to provide a dependable and efficient testing solution in the face of virus crises such as the current COVID-19 pandemic. The company's dedication to leveraging cutting-edge technology to address pressing global healthcare needs reflects a commitment to innovation and societal impact. While details about the last investment and investors are not available at this time, the potential of SPEKTRAX in addressing the critical need for rapid and reliable COVID-19 testing solutions could make it an attractive opportunity for venture capital firms looking to invest in impactful biotechnology startups.

Taxonomy: COVID-19, rapid test kit, nanotechnology, diagnostic tool, pandemic response, public health, handheld device, medical innovation

No funding data available for SPEKTRAX yet.

Get notified when SPEKTRAX raises funding

SPEKTRAX Alternatives & Competitors

SPEKTRAX vs
Rainier Rehabilitation
Rainier Rehabilitation

Protected together! With the recent introduction of the COVID-19 Vaccines, resident and staff covid...

19 employees
Health Care
SPEKTRAX vs
Red Cell Biotechnology
Red Cell Biotechnology Turkey

Redcell BIOTECHNOLOGY manufactures products such as blood grouping gel cards, brucellosis diagnostic...

7 employees
SPEKTRAX vs
ANA Therapeutics
ANA Therapeutics United States

We’re investigating niclosamide as a treatment for COVID-19.

Seed
2-10 employees
Biotechnology, Health Care

FAQ About SPEKTRAX

SPEKTRAX is creating an ultra-rapid COVID-19 test kit with a handheld device that takes minutes to produce results.
SPEKTRAX was founded in 2020.
SPEKTRAX is headquartered in The Netherlands.
SPEKTRAX operates in the following industries: Biotechnology.
SPEKTRAX has approximately 11-50 employees.
Top alternatives and competitors to SPEKTRAX include Rainier Rehabilitation, Red Cell Biotechnology, ANA Therapeutics, PAG Consulting Inc, Sick.org. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
SPEKTRAX and Rainier Rehabilitation are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors SPEKTRAX and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy